The objective of this study was to analyze whether inhibitory and activating killer cell immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I alleles defined by their KIR binding motifs are associated with multiple sclerosis (MS) susceptibility or severity.
Method:
We performed a population-based case–control study in 321 patients with clinically isolated syndrome (CIS) and clinically definite MS (CDMS) and 156 healthy blood donors (HD). Inhibitory and activating KIRs and HLA class I alleles were genotyped using polymerase chain reaction (PCR) sequence-specific primers. Allelic frequencies were correlated with prevalence, age of onset, disability and disease duration of CIS and CDMS.
Results:
The frequency of the inhibitory KIR2DL3 gene was significantly reduced in patients with CIS and CDMS (p = 3.1 × 10−5). KIR2DL3-dependent risk reduction remained significant after elimination of patients carrying MS-associated DRB1*15, DRB1*03, DRB1*01 alleles. In addition, individuals carrying two copies for KIR2DL2/KIR2DS2 but lacking KIR2DL3 were overrepresented in the CIS/CDMS cohort. However, both genes did not affect disease risk in presence of KIR2DL3. We did not detect any association between the presence or absence of KIR genes with clinical disease parameters.
Conclusion:
Absence of the inhibitory KIR2DL3 gene is associated with the development of CIS/CDMS. These findings, if confirmed in larger cohorts, suggest that KIR-mediated recognition of HLA class I molecules should be further explored as potential disease mechanism in MS.
DymentDAEbersGCSadovnickAD. Genetics of multiple sclerosis. Lancet Neurol2004; 3: 104–110.
2.
OksenbergJRBaranziniSESawcerSHauserSL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet2008; 9: 516–526.
3.
JersildCFogTHansenGSThomsenMSvejgaardADupontB. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet1973; 2: 1221–1225.
4.
FuggerLFrieseMABellJI. From genes to function: the next challenge to understanding multiple sclerosis. Nat Rev Immunol2009; 9: 408–417.
5.
LanierLL. NK cell recognition. Annu Rev Immunol2005; 23: 225–274.
6.
MorettaAMarcenaroEParoliniSFerlazzoGMorettaL. NK cells at the interface between innate and adaptive immunity. Cell Death Differ2008; 15: 226–233.
7.
UhrbergMValianteNMShumBP. Human diversity in killer cell inhibitory receptor genes. Immunity1997; 7: 753–763.
8.
YenJHMooreBENakajimaT. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med2001; 193: 1159–1167.
9.
MartinMPNelsonGLeeJH. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol2002; 169: 2818–2822.
10.
KhakooSIThioCLMartinMP. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science2004; 305: 872–874.
11.
KulkarniSMartinMPCarringtonM. The Yin and Yang of HLA and KIR in human disease. Semin Immunol2008; 20: 343–352.
12.
Martinez-RodriguezJESaez-BorderiasAMunteisERomoNRoquerJLopez-BotetM. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy. Clin Immunol2010; 137: 41–50.
13.
PolmanCHReingoldSCEdanG. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol2005; 58: 840–846.
14.
RoxburghRHSeamanSRMastermanT. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
15.
HsuKCLiuXRSelvakumarAMickelsonEO’ReillyRJDupontB. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol2002; 169: 5118–5129.
16.
UhrbergMParhamPWernetP. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics2002; 54: 221–229.
17.
SingleRMMartinMPMeyerDGaoXCarringtonM. Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics2008; 60: 711–725.
ParhamP. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol2005; 5: 201–214.
20.
MartinMPGaoXLeeJH. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet2002; 31: 429–434.
21.
SpeiserDEValmoriDRimoldiD. CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol1999; 29: 1990–1999.
22.
HuardBKarlssonL. KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature2000; 403: 325–328.
23.
HuardBKarlssonL. A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol2000; 30: 1665–1675.
24.
KarabonLJedynakAGiebelS. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens2011; 78: 129–138.
25.
JennesWVerheydenSDemanetC. Low CD4+ T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands. PLoS One2011; 6: e17043.
26.
WinterCCGumperzJEParhamPLongEOWagtmannN. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol1998; 161: 571–577.
27.
MoestaAKNormanPJYawataMYawataNGleimerMParhamP. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol2008; 180: 3969–3979.
28.
LorentzenARKarlsenTHOlssonM. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol2009; 65: 658–666.
29.
JiaoYLMaCYWangLC. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol2008; 28: 343–349.
30.
JiaoYLZhangBCYouL. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol2010; 30: 840–844.
31.
JonesDCEdgarRSAhmadT. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immunity2006; 7: 576–582.
32.
KimotoYHoriuchiTTsukamotoH. Association of killer cell immunoglobulin-like receptor 2DL5 with systemic lupus erythematosus and accompanying infections. Rheumatology (Oxford)2010; 49: 1346–1353.
33.
LoweDPCookMABowmanSJBriggsDC. Association of killer cell immunoglobulin-like receptors with primary Sjogren’s syndrome. Rheumatology (Oxford)2009; 48: 359–362.
34.
MerinoAMalhotraRMortonM. Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples. J Infect Dis2011; 203: 487–495.
35.
MomotTKochSHunzelmannN. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum2004; 50: 1561–1565.
36.
MousaviTPoormoghimHMoradiMTajikNShahsavarFAsadifarB. Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against ankylosing spondylitis. Iran J Immunol2010; 7: 88–95.
SantinICastellanos-RubioAPerez de NanclaresGVitoriaJCCastanoLBilbaoJR. Association of KIR2DL5B gene with celiac disease supports the susceptibility locus on 19q13.4. Genes Immunity2007; 8: 171–176.
39.
SuzukiYHamamotoYOgasawaraY. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol2004; 122: 1133–1136.
40.
TaniguchiMKawabataM. KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium-positive individuals in malaria infection. Immunogenetics2009; 61: 717–730.
41.
YenJHMooreBENakajimaT. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med2001; 193: 1159–1167.
42.
ZvyaginIVMamedovIZBritanovaOV. Contribution of functional KIR3DL1 to ankylosing spondylitis. Cell Mol Immunol2010; 7: 471–476.
43.
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature2007; 447: 661–678.
44.
SawcerS. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain2008; 131: 3118–3131.
